# Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo

> **NCT07075289** · PHASE4 · COMPLETED · sponsor: **Universitas Sebelas Maret** · enrollment: 44 (actual)

## Conditions studied

- Benign Paroxysmal Positional Vertigo (Disorder)

## Interventions

- **DRUG:** DLBS1033
- **DRUG:** Betahistine Mesylate tablet

## Key facts

- **NCT ID:** NCT07075289
- **Lead sponsor:** Universitas Sebelas Maret
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-01
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-12-27
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2025-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07075289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07075289, "Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07075289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*